Annual General Meeting 2010: Tecan shareholders endorse all motions proposed by the Board of Directors

• An increase in the dividend from CHF 0.90 to CHF 1.00 per registered share
• All Board members re-elected for a term of one year; Rolf Classon confirmed  as Chairman
• Articles of Incorporation amended in line with the Book Entry Securities Act
• Authorized share capital extended for a further two years

Männedorf, Switzerland, April 21, 2010 – The Annual General Meeting of Tecan Group AG (SIX Swiss Exchange: TECN) has today endorsed all motions proposed by the Board of Directors. The shareholders approved the Annual Report, the financial statements and the consolidated financial statements and granted discharge to the Board of Directors and the Executive Committee. Shareholders approved an increase in the dividend for fiscal year 2009 to CHF 1.00 per registered share, up from CHF 0.90 the previous year. The Board of Directors had proposed this increase on the basis of the company’s healthy balance sheet and the sustainable good business perspective. The payout will take place on April 28, 2010.

All the members of the Board of Directors were re-elected for a term of one year. Immediately after the Annual General Meeting, Rolf Classon was confirmed as Chairman by the Board.

Shareholders also approved an amendment to the Articles of Incorporation which had become necessary due to the entry into force of the Book Entry Securities Act.

Shareholders also agreed to extend the authorized share capital for a further two years and amend the Articles of Incorporation accordingly, which will allow Tecan sufficient flexibility to finance acquisitions. The authorized capital was created in 2006 and extended for a further two years at the Annual General Meeting 2008.

KPMG AG, Zurich, was confirmed as statutory auditor for 2010. 

Next date for the diary

The 2010 Interim Report will be published on August 12, 2010.

About Tecan

Tecan (www.tecan.com) is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics. The company specializes in the development, production and distribution of instruments and automated workflow solutions for laboratories in the life sciences sector. With its subsidiary REMP (www.remp.com), Tecan is the market leader in automated laboratory storage and logistics systems. Its clients include pharmaceutical and biotechnology companies, university research departments, forensic and diagnostic laboratories. As an original equipment manufacturer, Tecan is also a leader in developing and manufacturing OEM instruments and components that are then distributed by partner companies. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both Europe and North America and maintains a sales and service network in 52 countries. In 2009, Tecan generated sales of CHF 392 million (USD 361.2 million; EUR 259.6 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TK: TECN/Reuters: TECZn.S/ ISIN CH0012100191).

For further information please contact